

Accepted Manuscript

Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy - A Single Center Registry

Dalene M. Bott-Kitslaar, APRN, CNP, Rayya A. Saadiq, DO, Robert D. McBane, MD, Charles L. Loprinzi, MD, Aneel A. Ashrani, MD, Teresa R. Ransone, PA-C, Alissa A. Wolfgram, RN, Michelle M. Berentsen, RN, Waldemar E. Wysokinski, MD

PII: S0002-9343(16)30024-9

DOI: [10.1016/j.amjmed.2015.12.025](https://doi.org/10.1016/j.amjmed.2015.12.025)

Reference: AJM 13328

To appear in: *The American Journal of Medicine*

Received Date: 6 December 2015

Revised Date: 16 December 2015

Accepted Date: 17 December 2015

Please cite this article as: Bott-Kitslaar DM, Saadiq RA, McBane RD, Loprinzi CL, Ashrani AA, Ransone TR, Wolfgram AA, Berentsen MM, Wysokinski WE, Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy - A Single Center Registry, *The American Journal of Medicine* (2016), doi: 10.1016/j.amjmed.2015.12.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Manuscript Title: Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy - A Single Center Registry

Authors: Dalene M. Bott-Kitslaar APRN, CNP¹, Rayya A. Saadiq DO¹, Robert D. McBane MD¹, Charles L. Loprinzi MD², Aneel A. Ashrani MD³, Teresa R. Ransone PA-C¹, Alissa A. Wolfgram RN¹, Michelle M. Berentsen RN¹, Waldemar E. Wysokinski MD¹

¹ Gonda Vascular Center, Thrombophilia Clinic, Division of Cardiovascular Diseases, Mayo Clinic Rochester, MN; ²Division Oncology, Mayo Clinic Rochester, MN; ³Division of Hematology, Mayo Clinic, Rochester, MN

Running Head: Rivaroxaban for Venous Thromboembolism with Malignancy

Key Words: venous thromboembolism, malignancy, direct oral anticoagulants, rivaroxaban

Conflict of interest:

- Waldemar Wysokinski has received consultation fees from Daiichi Sankyo, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc.

- All other authors have no conflicts associated with this publication

Funding: This work was partially supported by the discretionally fund from Gonda Vascular Center, Mayo Clinic Rochester

All authors had access to the data and approved the current version of the manuscript. Dalene M. Bott-Kitslaar was instrumental in data collection and assessment, prepared the first version of the manuscript. Dr. Rayya Saadiq helped with clinical data collection, statistical analysis and preparation of the first version of the manuscript. Dr. Robert McBane was instrumental in protocol generation, data analysis and manuscript preparation revising it critically for important intellectual content. Dr. Charles Loprinzi helped with data analysis and manuscript preparation revising it critically for important intellectual content. Dr. Aneel A. Ashrani helped with data analysis and manuscript preparation revising it critically for important intellectual content. Teresa Ransone, Alissa Wolfgram, and Michelle Berentsen were instrumental in data collection, and preparation of the final version of the manuscript. Dr. Wysokinski provided oversight of protocol generation, data collection, and manuscript preparation.

Corresponding author:

Waldemar E. Wysokinski MD

Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic

200 First Street

Rochester, MN 55905

Tel: (507) 266 - 3964

wysokinski.waldemar@mayo.edu

Download English Version:

<https://daneshyari.com/en/article/5877484>

Download Persian Version:

<https://daneshyari.com/article/5877484>

[Daneshyari.com](https://daneshyari.com)